NRXS
AMEXNeuraxis Inc.
Price$6.76-0.05 (-0.73%)
01:45 PM07:45 PM
News · 26 weeks31-100%
2025-12-142026-06-07
Mix1890d
- SEC Filings7(39%)
- Earnings4(22%)
- Insider4(22%)
- Other2(11%)
- Dividends1(6%)
Latest news
25 items- PRNeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue GrowthCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter period ended March 31, 2026. 1Q26 Financial Highlights Revenues increased 80% year over year to $1.6M, reflecting the AMA Category I CPT® code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payor coverage.Expanded gross margin by 200 basis points and improved operating loss by 24% year over year as more IB-Stim® devices were sold a
- SECSEC Form 10-Q filed by Neuraxis Inc.10-Q - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, May 12, 2026, at 9:00am ET Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060Webcast: https:
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
- INSIDERDirector Aharon Gil was granted 234,221 shares, increasing direct ownership by 57% to 33,902 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- SECSEC Form DEFA14A filed by Neuraxis Inc.DEFA14A - Neuraxis, INC (0001933567) (Filer)
- SECSEC Form DEF 14A filed by Neuraxis Inc.DEF 14A - Neuraxis, INC (0001933567) (Filer)
- SECNeuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis Expands Payer Coverage with Four New Medical PoliciesCARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced four additional health insurers with medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 1.25 million covered lives. These medical policies expand incremental access to IB-Stim treatment for beneficiaries in West Virginia, New Hampshire, South Carolina, Virginia, and Florida. "Momentum in expanding insurance coverage for IB-Stim remains strong as we work to make this therapy m
- SECNeuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Neuraxis, INC (0001933567) (Filer)
- SECSEC Form 424B5 filed by Neuraxis Inc.424B5 - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis, Inc. Announces Preferred Stock DividendCARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock. Holders of record of the Company's Series B Preferred Stock (the "Series B Preferred Stock") as of the close of business on April 21, 2026 will receive a stock dividend of the Company's common stock, par value $0.001 per share (the "Common Stock"), for every one share of Series B Preferred Stock held. The number of shares of Common Stoc
- INSIDERSEC Form 4 filed by Henrichs Timothy Robert4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Carrico Thomas Joeseph4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Carrico Brian Allen4 - Neuraxis, INC (0001933567) (Issuer)
- PRNeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial ResultsCARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025. 4Q25 Financial Highlights Revenues increased 27% year over year to $968 thousand in 4Q25.Operating loss increased 17% year over year, primarily due to higher selling expenses directly related to increased sales volume and compensation expenses to facilitate growth. Cash balance was $5.0 million as of December 31, 2025. FY2025 Financial Highlights
- SECSEC Form 10-K filed by Neuraxis Inc.10-K - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2025, for the period ended December 31, 2025, on Thursday, March 19, 2026, before market open. The Company has scheduled a conference call for the same day, Thursday, March 19, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Thursday, March 19, 2026, at 9:00am ET Live Webcast Information: Interested parties can access the confere
- INSIDERSEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Watkins Bradley Mitchell was granted 21,598 shares, increasing direct ownership by 87% to 46,335 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CRO, CCO, CPO Carrico Thomas Joeseph4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Carrico Brian Allen4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Keyser Jane Elizabeth was granted 21,598 shares, increasing direct ownership by 87% to 46,335 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERLarge owner Hannasch Brian bought $382,800 worth of shares (80,000 units at $4.79), increasing direct ownership by 7% to 1,211,522 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
NRXS FAQ
5 questionsWhere does NRXS stock trade?
Neuraxis Inc. (NRXS) is listed on AMEX.What sector and industry is NRXS in?
Neuraxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Neuraxis Inc. go public?
Neuraxis Inc. (NRXS) completed its IPO in 2023.What companies are similar to NRXS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NRXS side-by-side with any of them on Quantisnow.How can I track NRXS on Quantisnow?
Quantisnow aggregates Neuraxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRXS to receive live email and push alerts on every new disclosure.